Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors

This publication has 17 references indexed in Scilit:

• Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer.
  2007
• Listeria monocytogenesas a vector for tumor-associated antigens for cancer immunotherapy
  Expert Review of Vaccines, 2006
• Regression of HPV-Positive Tumors Treated With a New Listeria monocytogenes Vaccine
  JAMA Otolaryngology–Head & Neck Surgery, 2004
• Immune evasion in human papillomavirus-associated cervical cancer
  Nature Reviews Cancer, 2002
• Two Listeria monocytogenes Vaccine Vectors That Express Different Molecular Forms of Human Papilloma Virus-16 (HPV-16) E7 Induce Qualitatively Different T Cell Immunity That Correlates with Their Ability to Induce Regression of Established Tumors Immortalized by HPV-16
  The Journal of Immunology, 2001
• The Pathogenesis of Advanced Cervical Cancer Provides the Basis for an Empirical Therapeutic Vaccine
  Experimental and Molecular Pathology, 2001
• Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers
  JNCI Journal of the National Cancer Institute, 2000
• Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.
  1996
• A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours
  Nature Medicine, 1995
• Immunity to Intracellular Bacteria
  Annual Review of Immunology, 1993